BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck CancerBenzinga • 05/21/21
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal CancerBusiness Wire • 05/21/21
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone LymphomaBusiness Wire • 05/19/21
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 VaccinesSeeking Alpha • 05/10/21
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian CancerBusiness Wire • 05/07/21
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer StudiesBenzinga • 04/28/21
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic LeukemiaBusiness Wire • 04/28/21
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021Business Wire • 04/12/21
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021Business Wire • 04/11/21
BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 StudyBenzinga • 04/08/21
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström's MacroglobulinemiaBusiness Wire • 04/08/21
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary DistressBusiness Wire • 04/08/21
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, ChinaBusiness Wire • 04/07/21
Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor StudyBenzinga • 03/24/21
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021Business Wire • 03/10/21
Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls24/7 Wall Street • 03/08/21
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung CancerBusiness Wire • 03/05/21
